Kazia says paxalisib posts 100% clinical benefit rate in six-patient phase 1b metastatic TNBC study
KZIA•Safety and next steps
Safety looked supportive, with no treatment-related serious adverse events reported in the initial group.
Enrollment for the ongoing paxalisib combination study is expected to finish by July 2027, with interim updates planned in 2026-2027.
Phase 1b data show clinical benefit in all evaluable patients
Kazia reported early Phase 1b data showing all six evaluable patients with advanced triple-negative breast cancer derived clinical benefit on paxalisib.
Most patients saw tumors shrink, including one complete response that has remained in remission since November 2025.
